InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
REAGAN Free
08/18/23 2:46 PM
Post #6,351
profile icon
Monksdream PremiumMember
08/16/23 12:31 PM
Post #6,350
profile icon
TimeFades Free
08/08/23 4:44 PM
Post #6,349
profile icon
TimeFades Free
08/04/23 10:55 AM
Post #6,348
profile icon
TimeFades Free
08/04/23 9:35 AM
Post #6,347
profile icon
willlbone Free
08/03/23 1:53 PM
Post #6,346
profile icon
AJ Freely Free
08/01/23 7:58 AM
Post #6,345
profile icon
cfoofme Free
07/09/22 2:57 PM
Post #6,344
profile icon
cfoofme Free
07/08/22 7:30 PM
Post #6,343
profile icon
mik1234 Free
10/22/21 10:51 PM
Post #6,342
profile icon
INFINITI Free
08/30/21 7:22 AM
Post #6,341
profile icon
mik1234 Free
08/27/21 2:46 PM
Post #6,340
profile icon
mik1234 Free
08/26/21 6:22 AM
Post #6,339
profile icon
Pt3 Free
08/24/21 4:11 PM
Post #6,338
profile icon
INFINITI Free
08/24/21 3:32 PM
Post #6,337
profile icon
INFINITI Free
08/24/21 3:32 PM
Post #6,336
profile icon
Hercules1 PremiumMember
08/24/21 3:24 PM
Post #6,335
profile icon
Pt3 Free
08/24/21 3:07 PM
Post #6,334
profile icon
INFINITI Free
08/24/21 3:05 PM
Post #6,333
profile icon
Pt3 Free
08/24/21 1:49 PM
Post #6,332
profile icon
INFINITI Free
08/24/21 9:47 AM
Post #6,331
profile icon
INFINITI Free
08/24/21 9:04 AM
Post #6,330
profile icon
INFINITI Free
08/24/21 8:45 AM
Post #6,329
profile icon
make it happen Free
08/24/21 8:40 AM
Post #6,328
profile icon
make it happen Free
08/24/21 8:39 AM
Post #6,327
profile icon
INFINITI Free
08/24/21 7:52 AM
Post #6,326
profile icon
Warrens Free
04/21/21 6:49 PM
Post #6,325
profile icon
Warrens Free
04/20/21 12:12 PM
Post #6,324
profile icon
ClayTrader Free
04/05/21 4:49 PM
Post #6,323
profile icon
Dubster watching Free
03/11/21 11:06 AM
Post #6,322
profile icon
Iron heart Free
03/03/21 3:58 AM
Post #6,321
profile icon
Roadtojourney Free
02/16/21 4:53 PM
Post #6,319
profile icon
Paullee Free
02/11/21 11:05 AM
Post #6,318
profile icon
Roadtojourney Free
02/11/21 10:50 AM
Post #6,317
profile icon
ClayTrader Free
02/10/21 4:38 PM
Post #6,316
profile icon
Stock_Barber PremiumMember
02/10/21 12:56 PM
Post #6,315
profile icon
Hercules1 PremiumMember
02/10/21 12:01 PM
Post #6,314
profile icon
NicksterPDX Free
02/10/21 10:57 AM
Post #6,313
profile icon
cfoofme Free
02/10/21 9:54 AM
Post #6,312
profile icon
NicksterPDX Free
02/10/21 9:52 AM
Post #6,311
profile icon
cfoofme Free
02/10/21 9:50 AM
Post #6,310
profile icon
jonny_red Free
01/06/21 8:34 AM
Post #6,309
profile icon
jonny_red Free
01/05/21 3:00 PM
Post #6,308
profile icon
zino Free
01/05/21 11:08 AM
Post #6,307
profile icon
mik1234 Free
12/09/20 3:32 PM
Post #6,306
profile icon
sanderburwil Free
12/09/20 3:15 PM
Post #6,305
profile icon
mik1234 Free
11/20/20 1:57 PM
Post #6,304
profile icon
blairsoldman Free
11/19/20 11:39 AM
Post #6,303
profile icon
alex1940 Free
11/06/20 8:59 AM
Post #6,302

Bio Path Holdings Inc (BPTH)

Followers
100
Posters
331
Posts (Today)
0
Posts (Total)
6351
Created
03/26/13
Type
Free
Moderators




Bio-Path is engaged in the business of financing and commercializing novel cancer therapeutics acquired from MD Anderson Cancer Center. Their first Antisense drug BP-1001, known as Prexigebersen has completed a partial phase II combination trial (with LDAC). The interim results demonstrated 47% of the patients showed early anti-leukemic activity.


http://www.biopathholdings.com/wp-content/uploads/2018/04/BPTH_Interim_Phase_2_AML_Data_Release.pdf 

The Prexigebersen phase II trials for AML are located at MD Anderson, Weill Cornell Medical College Presbyterian Hospital, Baylor, New Jersey Hematology Oncology Associates, West Virginia University and University of Kansas.

Bio-Path Holdings is focused on antisense drugs which work at a cellular level to interrupt protein production by the diseased cell. The lead drug, Prexigebersen is targeting the Grb-2 protein. Bio Path Holdings' delivery system is a small molecule neutral liposome system. Through the phase 2 of the combination trial for Prexigebersen there has been absolutely no toxicity. The results of testing performed by Bio Path demonstrates an uptake of the drug at a cellular level. The pErk results demonstrate not only a 50+% knockdown of the target protein but shows the pathway was shut down validating the delivery system. The purpose of phase 2 will be to test the effectiveness of the drug. Interim results are positive.

A CML combination drug safety study with Sprycel (Dasatinib) for Prexigebersen has begun at MD Anderson.

Patent protection for manufacturing their neutral lipid delivery system has been granted.


http://www.biopathholdings.com

This link to the company website describes their delivery technology:


http://biopathholdings.com/technology/


The company was founded on the technology from M.D. Anderson Cancer Center at the University of Texas in Houston. M.D. Anderson is the largest insitutional shareholder. After raising additional funds the company has 2+ million in cash. BIO-PATH'S viability is in question due to a lack of funds.

 
Bio-Path Holdings does not manufacture their drugs but uses contractors, hence the need for partners.
 
BPTH is presently traded on the NASDAQ.

Here are links to articles on their drug technology:


http://www.abstractsonline.com/pp8/#!/4292/presentation/2610

http://www.biopathholdings.com/wp-content/uploads/2017/06/Published-Article-Evolution-of-Antisense-in-Oncology.pdf

http://www.biopathholdings.com/wp-content/uploads/2018/03/BPTH_Lancet_20180329.pdf


Stone Gate Capital "under valued"
https://finance.yahoo.com/news/stonegate-capital-partners-updates-coverage-213000664.html        
https://investorshub.advfn.com/75fb7cf5-a8b2-4eb3-b48e-3bb1403ff45a"="" rel="nofollow" target="_blank">; style="height:1.200000; width:234.840000">

Our press releases-See Links here
http://www.biopathholdings.com/press-release/


Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

 
 

 

Most Liked Posts
(Last 30 Days)
Volume:
Day Range:
Last Trade Time:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Most Liked Posts
(Last 30 Days)
New Post